Trial Leopard-II

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

Leopard-II

Full title

Definitive Radiochemotherapie mit 5-FU / Cisplatin plus/minus Cetuximab bei inoperablem, lokal fortgeschrittenem Speiseröhrenkrebs: eine Phase-II-Studie

EudraCT number

2010-023427-18

NCT number

NCT01787006

Responsible organization

Klinik f.Strahlentherapie, Telefon: 089440074521

Indications

Classification	Code	Description
ICD-10-GM	C15.-	Bösartige Neubildung des Üsophagus
-		Gastrointestinal tumors
-		Esophageal cancer

Trial design

Trial type

Interventional

Blinding type

Open

Phase

Status

Trial finished

Votes

Institutional review board - vote

Unknown

Initiiation & lock

Date of lock (planned / actual)

2018-09-06 / 2018-09-06

Participants

	Function	Prename	Surname	Organization
	Principal Investigator	CLAUS	BELKA	Keine Organisationseinheit angegeben